Medication for borderline personality disorder: A survey at a secure hospital

  title={Medication for borderline personality disorder: A survey at a secure hospital},
  author={Camilla M. Haw and Jean Stubbs},
  journal={International Journal of Psychiatry in Clinical Practice},
  pages={270 - 274}
  • C. HawJ. Stubbs
  • Published 10 October 2011
  • Psychology, Medicine
  • International Journal of Psychiatry in Clinical Practice
Abstract Objectives. To study the use of medication in the treatment of inpatients with borderline personality disorder (BPD). To survey clinicians’ views on the UK National Institute for Health and Clinical Excellence (NICE) Guideline on BPD. Methods. Cross-sectional survey of the use of psychotropics purely for BPD at a large secure UK psychiatric hospital, together with interviews with the treating psychiatrists. Results. A total of 79 patients had a DSM diagnosis of BPD, of whom 80% were… 

Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines

A positive association between the number of medications and the effectiveness of the inpatient treatment program, as well as the absence of a relationship between number of medication and comorbidity contradicts the often suggested iatrogenic effect of polypharmacy.

Pharmacological treatment of borderline personality disorder: a retrospective observational study at inpatient unit in Italy

Mood stabilizers showed a more favourable profile in terms in length of stay in hospital than antipsychotic and/or antidepressant medication, and the discrepancy between international recommendations and everyday clinical practice is reiterated.

Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices

In total, 94% of BPD patients were treated with psychotropic medication, and psychiatrists predominantly saw an indication to prescribe antidepressants, followed by antipsychotics, mood stabilizers, and benzodiazepines.

Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders

The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors

This review paper describes the state of prescribing practice in Borderline Personality Disorder (BPD), wherein medications are prescribed far more than either evidence or practice guidelines would

Off-Label Use of Second-Generation Antipsychotics in Borderline Personality Disorder: A Survey of Italian Psychiatrists.

The results reiterate the discrepancy between everyday clinical practice and international recommendations, and show how relevant the literature is in off-label drug prescription.

Psychotropic medication use in hospitalized patients with borderline personality disorder

Increased medication utilization among patients with BPD is found and polypharmacy may increase the risk of side effects, drug interactions, and drug toxicity for BPD patients.

Prescribing Practices for Patients With Borderline Personality Disorder During Psychiatric Hospitalizations.

Prescribing practices during acute psychiatric hospitalization in a large cohort of patients with borderline personality disorder at a tertiary care psychiatry unit from January 1, 2013, throughJanuary 1, 2015 are understood.

Experiences of women in secure care who have been prescribed clozapine for borderline personality disorder

When psychological interventions are, at least initially, ineffective then clozapine treatment is likely to be evaluated positively by a group of women with borderline personality disorder in secure care despite the potential disadvantages.



Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials

The current evidence from randomised controlled trials suggests that drug treatment, especially with mood stabilisers and second-generation antipsychotics, may be effective for treating a number of core symptoms and associated psychopathology, but the evidence does not currently support effectiveness for overall severity of borderline personality disorder.

Treatment histories of borderline inpatients.

It is suggested that particularly high rates of costly inpatient treatment are associated with a complex admixture of older age, BPD symptoms in the cognitive and impulse realms, and traumatic life experiences occurring in both childhood and adulthood.

Use of psychotropic medication among psychiatric out-patients with personality disorder

Medication is commonly prescribed to people with personality disorder but more needs to be known about why prescriptions are started and stopped, what the benefits are, and how these are judged by patients and care teams.

Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder.

The preliminary but nonetheless favorable results suggest that clozapine deserves careful consideration for a controlled study in patients with borderline personality disorder and psychoses, especially if the clinical issues include severe self-mutilation, aggression, and violence.

Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years.

The results of this study suggest that the majority of borderline patients continue to use outpatient treatment in a sustained manner through 6 years of follow-up, but only a declining minority use more restrictive and costly forms of treatment.

Axis I comorbidity of borderline personality disorder.

The results suggest that the lifetime pattern of axis I comorbidity characteristic of borderline patients and distinguishing for the disorder is a particularly good marker for borderline personality disorder.

Borderline personality disorder: health service use and social functioning among a national household population

Functional effects of BPD are mediated through co-morbid clinical syndromes, not Axis II psychopathology.

Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder.

Low-dose clozapine for acute and continuation treatment led to improvement in overall symptomatology in a small sample of severe BPD patients, coupled with an overall improvement.

[Axis I comorbidity in borderline personality disorder].

The comorbidity of Axis I diagnoses and borderline personality disorder was found to be high and was significantly associated with mood, anxiety and substance use disorders.